Furamidine (DB75) is a selective and cell-permeable inhibitor of protein arginine methyltransferase 1 (PRMT1) (IC50 = 9.4 μM), with higher selectivity over PRMT5 (IC50 = 166 μM), PRMT6 (IC50 = 283 μM), and PRMT4/CARM1 (IC50 > 400 μM); it is also a potent, reversible, and competitive inhibitor of tyrosyl-DNA phosphodiesterase 1 (TDP1), effective against both single-stranded and double-stranded DNA substrates, with stronger activity on double-stranded DNA; additionally, Furamidine exhibits antiparasitic activity; it inhibits the growth of most leukemia cell lines (e.g., Meg-01, K562, HL-60, NB4, MOLM13, CMK, CMY, CMS, CHRF) except HEL cells harboring JAK2 V617F mutations; it reduces the expression of methylated GFP-ALY protein in 293T cells; in combination with Irinotecan, it suppresses proteinuria and prolongs survival in lupus-prone NZB/NZW mice.